impact of ugt1a9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients

Authors

talia mazidi department of clinical pharmacy, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran.

mohammad-reza rouini professor of pharmaceutics, department of pharmaceutics, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran.

mohammad-hossein ghahremani associate professor, department of toxicology & pharmacology, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran.

simin dashti-khavidaki department of clinical pharmacy, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran.

abstract

there are wide individual differences in pharmacokinetic parameters of mycophenolate mofetil (mmf) among transplanted patients. some studies have shown that single nucleotide polymorphisms (snps) of the uridine diphosphate glucuronosyl transferase1a9 (ugt1a9) are responsible for these differences in early days after transplantation. therefore it was decided to evaluate the influence of ugt polymorphism on mmf pharmacokinetics among stable iranian transplant patients. this was a cross sectional study from march 2008 through december 2008 in imam khomeini hospital affiliated to the tehran university of medical sciences in iran. blood samples were taken from 40 de novo stable iranian renal transplant patients taking 2 g mmf daily with srcr£1.4 mg/dl with at least 3 months history of transplantation. appropriate pcr and hplc methods were used for the determination of snps and their impact on mpa pharmacokinetics. t-275a polymorphism occurred in 15% of patients, ugt1a9*3 occurred in 2.5% of patients. carriers of t-275a polymorphism had significant lower mpa auc 0-12 in comparison with non-carriers or wild type (73.3±17.8 mg/h/ml vs. 110.8±31.1 mg/h/ml, p = 0.006). there was no significant difference in auc 6-12 between the two groups although carriers of t-275a snp had lower mpa auc 6-12 (22.4±4.5 mg/h/ml vs. 26.8±10.2 mg/h/ml, p=0.24). cmax was lower in the carriers of (20.2±9.0 mg/ml vs. 37.2±12.5 mg/ml, p=0.004). there was no significant difference in c0 between two groups. (3.0±1.2 mg/ml vs. 3.9±1.6 mg/ml, p=0.1). this study in iranian stable transplanted patients shows that carriers of t-275a polymorphism had significantly lower mpa exposure compared to non-carriers.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients

There are wide individual differences in pharmacokinetic parameters of mycophenolate mofetil (MMF) among transplanted patients. Some studies have shown that single nucleotide polymorphisms (SNPs) of the Uridine Diphosphate Glucuronosyl Transferase1A9 (UGT1A9) are responsible for these differences in early days after transplantation. Therefore it was decided to evaluate the influence of UGT poly...

full text

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients

There are wide individual differences in pharmacokinetic parameters of mycophenolate mofetil (MMF) among transplanted patients. Some studies have shown that single nucleotide polymorphisms (SNPs) of the Uridine Diphosphate Glucuronosyl Transferase1A9 (UGT1A9) are responsible for these differences in early days after transplantation. Therefore it was decided to evaluate the influence of UGT poly...

full text

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients

There are wide individual differences in pharmacokinetic parameters of mycophenolate mofetil (MMF) among transplanted patients. Some studies have shown that single nucleotide polymorphisms (SNPs) of the Uridine Diphosphate Glucuronosyl Transferase1A9 (UGT1A9) are responsible for these differences in early days after transplantation. Therefore it was decided to evaluate the influence of UGT poly...

full text

Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients.

Mycophenolate mofetil (MMF) is a prodrug active only after its hydrolysis to mycophenolic acid (MPA). The UGT1A9 enzyme is of special interest since it is the main enzyme involved in the glucuronidation of MPA. Single nucleotide polymorphisms (SNPs) in the UGT1A9 gene may be responsible for individual differences in the pharmacokinetics of MMF. Expression levels and the activity of UGT1A9 may d...

full text

pharmacokinetic study of mycophenolic acid in iranian kidney transplant patients.

background: the purpose of this study was to characterize the pharmacokinetic parameters of mycophenolic acid (mpa) in iranian kidney transplant patients. methods: plasma mpa concentration of mycophenolate mofetile (mmf) 1 gram two times a day was measured in 21 iranian kidney transplant recipients receiving treatment. patients who entered the study had been transplanted for more than 3 months ...

full text

Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Different Formulations in Stable Renal Transplant Patients

Mycophenolic acid has gained widespread acceptance as the antimetabolite of choice in most of the immunosuppressive regimens, thanks to its selective action versus T and B cells. This drug is characterized by a narrow therapeutic index and a well-documented relationship between efficacy (in terms of acute rejection episodes) and exposure to mycophenolic acid (as AUC and C0). For these reasons, ...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of pharmaceutical research

جلد ۱۲، شماره ۳، صفحات ۵۴۷-۵۵۶

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023